Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials.

Sex-based differences in pulmonary arterial hypertension (PAH) are known, but the contribution to disease measures is understudied. We examined whether sex was associated with baseline 6-minute-walk distance (6MWD), hemodynamics, and functional class. We conducted a secondary analysis of participant-level data from randomized clinical trials of investigational PAH therapies conducted between 1998 and 2014 and provided by the U.S. Food and Drug Administration. Outcomes were modeled as a function of an interaction between sex and age or sex and body mass index (BMI), respectively, with generalized mixed modeling. We included a total of 6,633 participants from 18 randomized clinical trials. A total of 5,197 (78%) were female, with a mean age of 49.1 years and a mean BMI of 27.0 kg/m. Among 1,436 males, the mean age was 49.7 years, and the mean BMI was 26.4 kg/m. The most common etiology of PAH was idiopathic. Females had shorter 6MWD. For every 1 kg/m increase in BMI for females, 6MWD decreased 2.3 (1.6-3.0) meters ( < 0.001), whereas 6MWD did not significantly change with BMI in males (0.31 m [-0.30 to 0.92];  = 0.32). Females had lower right atrial pressure (RAP) and mean pulmonary artery pressure, and higher cardiac index than males (all  < 0.03). Age significantly modified the sex by RAP and mean pulmonary artery pressure relationships. For every 10-year increase in age, RAP was lower in males (0.5 mm Hg [0.3-0.7];  < 0.001), but not in females (0.13 [-0.03 to 0.28];  = 0.10). There was a significant decrease in pulmonary vascular resistance (PVR) with increasing age regardless of sex ( < 0.001). For every 1 kg/m increase in BMI, there was a 3% decrease in PVR for males ( < 0.001), compared with a 2% decrease in PVR in females ( < 0.001). Sexual dimorphism in subjects enrolled in clinical trials extends to 6MWD and hemodynamics; these relationships are modified by age and BMI. Sex, age, and body size should be considered in the evaluation and interpretation of surrogate outcomes in PAH.